In conclusion, this study shows, for the first time, miR-182-5p overexpression and related Cyld and Foxo1 downregulation in hepatic tissues and tumors obtained from diet-induced NAFLD/HCC mouse models, paving the way for further studies to assess the potential role of miR-182-5p as a biomarker or therapeutic target. The gene discussed is CYLD; the disease is metabolic dysfunction-associated steatotic liver disease.